Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences announced a proposed underwritten public offering of common stock or pre-funded warrants to raise capital. The company intends to use net proceeds to fund clinical trials, preclinical studies, manufacturing, and general corporate purposes.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.